Can long-term survival be improved in patients with small-cell lung cancer (SCLC) and good performance status? Medical Research Council Lung Cancer Working Party.

2.50
Hdl Handle:
http://hdl.handle.net/10541/108699
Title:
Can long-term survival be improved in patients with small-cell lung cancer (SCLC) and good performance status? Medical Research Council Lung Cancer Working Party.
Authors:
Bleehen, N M; Girling, D J; Gregor, A; Leonard, R C; Machin, D; McKenzie, C G; Morgan, D A; Smyth, J F; Spittle, M F; Stephens, R J; Thatcher, Nick
Abstract:
Results from a long-term follow-up suggest that in patients with limited small-cell lung cancer (SCLC) and normal performance status intensive alternating chemotherapy and radiotherapy improve long-term survival rates. In a non-randomised study, 22 patients with SCLC of limited extent and good performance status were prescribed six cycles of etoposide, doxorubicin, cisplatin and cyclophosphamide at 4 week intervals with doses of thoracic radiotherapy following the second, third and fourth cycles. Although only six patients received all their prescribed treatment, nine (41%) were alive at 1 year, seven (32%) at 2 years, six (27%) at 3 years, and four are still alive at, respectively, 42, 47, 50, and 61 months, all four being in the subgroup of eight patients with WHO performance status grade 0 at the start of treatment. In a comparison with similar patients receiving conventionally scheduled chemotherapy and radiotherapy in a concurrent trial, no difference in survival was seen in the patients with performance status grade 1 or 2, but a large difference in favour of the alternating schedule in those with grade 0 status was seen. We encourage other investigators to report the results achieved with intensive treatment in patients with WHO grade 0 performance status at the start of treatment.
Affiliation:
MRC Clinical Oncology and Radiotherapeutics Unit, Addenbrooke's Hospital, Cambridge, UK.
Citation:
Can long-term survival be improved in patients with small-cell lung cancer (SCLC) and good performance status? Medical Research Council Lung Cancer Working Party. 1994, 70 (1):142-4 Br. J. Cancer
Journal:
British Journal of Cancer
Issue Date:
Jul-1994
URI:
http://hdl.handle.net/10541/108699
PubMed ID:
8018526
Type:
Article
Language:
en
ISSN:
0007-0920
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorBleehen, N Men
dc.contributor.authorGirling, D Jen
dc.contributor.authorGregor, Aen
dc.contributor.authorLeonard, R Cen
dc.contributor.authorMachin, Den
dc.contributor.authorMcKenzie, C Gen
dc.contributor.authorMorgan, D Aen
dc.contributor.authorSmyth, J Fen
dc.contributor.authorSpittle, M Fen
dc.contributor.authorStephens, R Jen
dc.contributor.authorThatcher, Nicken
dc.date.accessioned2010-07-30T13:21:14Z-
dc.date.available2010-07-30T13:21:14Z-
dc.date.issued1994-07-
dc.identifier.citationCan long-term survival be improved in patients with small-cell lung cancer (SCLC) and good performance status? Medical Research Council Lung Cancer Working Party. 1994, 70 (1):142-4 Br. J. Canceren
dc.identifier.issn0007-0920-
dc.identifier.pmid8018526-
dc.identifier.urihttp://hdl.handle.net/10541/108699-
dc.description.abstractResults from a long-term follow-up suggest that in patients with limited small-cell lung cancer (SCLC) and normal performance status intensive alternating chemotherapy and radiotherapy improve long-term survival rates. In a non-randomised study, 22 patients with SCLC of limited extent and good performance status were prescribed six cycles of etoposide, doxorubicin, cisplatin and cyclophosphamide at 4 week intervals with doses of thoracic radiotherapy following the second, third and fourth cycles. Although only six patients received all their prescribed treatment, nine (41%) were alive at 1 year, seven (32%) at 2 years, six (27%) at 3 years, and four are still alive at, respectively, 42, 47, 50, and 61 months, all four being in the subgroup of eight patients with WHO performance status grade 0 at the start of treatment. In a comparison with similar patients receiving conventionally scheduled chemotherapy and radiotherapy in a concurrent trial, no difference in survival was seen in the patients with performance status grade 1 or 2, but a large difference in favour of the alternating schedule in those with grade 0 status was seen. We encourage other investigators to report the results achieved with intensive treatment in patients with WHO grade 0 performance status at the start of treatment.en
dc.language.isoenen
dc.subjectLung Canceren
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshCarcinoma, Small Cell-
dc.subject.meshCisplatin-
dc.subject.meshCombined Modality Therapy-
dc.subject.meshCyclophosphamide-
dc.subject.meshDoxorubicin-
dc.subject.meshDrug Administration Schedule-
dc.subject.meshEtoposide-
dc.subject.meshHumans-
dc.subject.meshLung Neoplasms-
dc.subject.meshProportional Hazards Models-
dc.subject.meshRadiotherapy Dosage-
dc.subject.meshRadiotherapy, High-Energy-
dc.subject.meshSurvival Analysis-
dc.subject.meshSurvival Rate-
dc.titleCan long-term survival be improved in patients with small-cell lung cancer (SCLC) and good performance status? Medical Research Council Lung Cancer Working Party.en
dc.typeArticleen
dc.contributor.departmentMRC Clinical Oncology and Radiotherapeutics Unit, Addenbrooke's Hospital, Cambridge, UK.en
dc.identifier.journalBritish Journal of Canceren

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.